{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:40:55Z","timestamp":1790991655256,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Soluble receptor for advanced glycation end products (sRAGE) is an anti-inflammatory factor that mitigates the proinflammatory effects of high mobility group box 1 (HMGB1). The aim of this study was to investigate whether Guillain-Barr\u00e9 syndrome (GBS)-related inflammation are mediated by sRAGE and HMGB1. We measured serum sRAGE, HMGB1, IL-6 and TNF-\u03b1 levels in 86 patients with GBS and analysed associations between sRAGE or HMGB1 and clinical variables in these subjects. In addition, we determined cerebrospinal fluid sRAGE and HMGB1 levels in a cross-sectional study of 50 patients with GBS who had matched serum samples. We found serum sRAGE levels in patients with the acute motor axonal neuropathy (AMAN) subtype of GBS, but not other subtypes, were significantly lower than those in healthy controls and were significantly correlated with GBS disability score and Erasmus GBS outcome score, while serum HMGB1, IL-6 and TNF-\u03b1 levels in all subtypes of GBS were significantly higher than those in healthy controls. Moreover, increased sRAGE levels and decreased HMGB1 levels after treatment were observed. Our results showed that serum sRAGE may be a useful biomarker for inflammation in the AMAN GBS subtype, while HMGB1 may be related to the inflammatory process across all types of GBS.<\/jats:p>","DOI":"10.1038\/srep21890","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T10:36:55Z","timestamp":1456223815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barr\u00e9 syndrome"],"prefix":"10.1038","volume":"6","author":[{"given":"Da-Qi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Qiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Na","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,23]]},"reference":[{"key":"BFsrep21890_CR1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","volume":"366","author":"RA Hughes","year":"2005","unstructured":"Hughes, R. A. & Cornblath, D. R. Guillain-Barre syndrome. Lancet 366, 1653\u20131666 (2005).","journal-title":"Lancet"},{"key":"BFsrep21890_CR2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneuroim.2010.09.017","volume":"231","author":"JB Winer","year":"2011","unstructured":"Winer, J. B. Guillain-Barre syndrome: clinical variants and their pathogenesis. J Neuroimmunol 231, 70\u201372 (2011).","journal-title":"J Neuroimmunol"},{"key":"BFsrep21890_CR3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/brain\/118.3.597","volume":"118","author":"TW Ho","year":"1995","unstructured":"Ho, T. W. et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118 (Pt 3), 597\u2013605 (1995).","journal-title":"Brain"},{"key":"BFsrep21890_CR4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000184748","volume":"32","author":"A McGrogan","year":"2009","unstructured":"McGrogan, A., Madle, G. C., Seaman, H. E. & de Vries, C. S. The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review. Neuroepidemiology 32, 150\u2013163 (2009).","journal-title":"Neuroepidemiology"},{"key":"BFsrep21890_CR5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/jnnp-2013-306212","volume":"85","author":"JS Bae","year":"2014","unstructured":"Bae, J. S. et al. Guillain-Barr\u00e9 syndrome in Asia. J Neurol Neurosurg Psychiatry 85(8), 907\u2013913 (2014).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFsrep21890_CR6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/jnnp.2010.238311","volume":"82","author":"M Capasso","year":"2011","unstructured":"Capasso, M., Notturno, F., Manzoli, C. & Uncini, A. Involvement of sensory fibres in axonal subtypes of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 82, 664\u2013670 (2011).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFsrep21890_CR7","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2174\/092986710791331086","volume":"17","author":"P Alexiou","year":"2010","unstructured":"Alexiou, P., Chatzopoulou, M., Pegklidou, K. & Demopoulos, V. J. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem 17, 2232\u20132252 (2010).","journal-title":"Curr Med Chem"},{"key":"BFsrep21890_CR8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","volume":"83","author":"A Bierhaus","year":"2005","unstructured":"Bierhaus, A. et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 83, 876\u2013886 (2005).","journal-title":"J Mol Med (Berl)"},{"key":"BFsrep21890_CR9","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1096\/fj.08-109033","volume":"22","author":"A Raucci","year":"2008","unstructured":"Raucci, A. et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22, 3716\u20133727 (2008).","journal-title":"FASEB J"},{"key":"BFsrep21890_CR10","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1096\/fj.08-109033","volume":"22","author":"A Raucci","year":"2008","unstructured":"Raucci, A. et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22, 3716\u20133727 (2008).","journal-title":"FASEB J"},{"key":"BFsrep21890_CR11","doi-asserted-by":"crossref","first-page":"L516","DOI":"10.1152\/ajplung.00118.2010","volume":"300","author":"N Yamakawa","year":"2011","unstructured":"Yamakawa, N., Uchida, T., Matthay, M. A. & Makita, K. Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 300, L516\u2013525 (2011).","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"BFsrep21890_CR12","doi-asserted-by":"crossref","unstructured":"Yan, S. F., Ramasamy, R. & Schmidt, A. M. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 79 (2010).","DOI":"10.1016\/j.bcp.2010.01.013"},{"key":"BFsrep21890_CR13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pharmthera.2013.11.001","volume":"141","author":"D Musumeci","year":"2014","unstructured":"Musumeci, D., Roviello, G. N. & Montesarchio, D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther 141, 347\u2013357 (2014).","journal-title":"Pharmacol Ther"},{"key":"BFsrep21890_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-5876-7-17","volume":"7","author":"LJ Sparvero","year":"2009","unstructured":"Sparvero, L. J. et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands and their role in cancer and inflammation. J Transl Med 7, 17, 1479-5876-7-17 (2009).","journal-title":"J Transl Med"},{"key":"BFsrep21890_CR15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/jnnp-2012-304039","volume":"84","author":"A Uzawa","year":"2013","unstructured":"Uzawa, A., Mori, M., Masuda, S., Muto, M. & Kuwabara, S. CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. J Neurol Neurosurg Psychiatry 84, 517\u2013522 (2013).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFsrep21890_CR16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/art.10859","volume":"48","author":"N Taniguchi","year":"2003","unstructured":"Taniguchi, N. et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48, 971\u2013981, (2003).","journal-title":"Arthritis Rheum"},{"key":"BFsrep21890_CR17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-065X.2007.00574.x","volume":"220","author":"ME Bianchi","year":"2007","unstructured":"Bianchi, M. E. & Manfredi, A. A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220, 35\u201346 (2007).","journal-title":"Immunol Rev"},{"key":"BFsrep21890_CR18","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1097\/BRS.0b013e318203941c","volume":"36","author":"KB Chen","year":"2011","unstructured":"Chen, K. B. et al. High-mobility group box-1 and its receptors contribute to proinflammatory response in the acute phase of spinal cord injury in rats. Spine (Phila Pa 1976) 36, 2122\u20132129 (2011).","journal-title":"Spine (Phila Pa 1976)"},{"key":"BFsrep21890_CR19","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1093\/emboj\/cdg516","volume":"22","author":"T Bonaldi","year":"2003","unstructured":"Bonaldi, T. et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22, 5551\u20135560 (2003).","journal-title":"EMBO J"},{"key":"BFsrep21890_CR20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.it.2005.04.009","volume":"26","author":"IE Dumitriu","year":"2005","unstructured":"Dumitriu, I. E., Baruah, P., Manfredi, A. A., Bianchi, M. E. & Rovere-Querini, P. HMGB1: guiding immunity from within. Trends Immunol 26, 381\u2013387 (2005).","journal-title":"Trends Immunol"},{"key":"BFsrep21890_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2005.01534.x","volume":"61","author":"R Kokkola","year":"2005","unstructured":"Kokkola, R. et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61, 1\u20139 (2005).","journal-title":"Scand J Immunol"},{"key":"BFsrep21890_CR22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0079-6603(08)60360-8","volume":"54","author":"M Bustin","year":"1996","unstructured":"Bustin, M. & Reeves, R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 54, 35\u2013100 (1996).","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"BFsrep21890_CR23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1189\/jlb.0908548","volume":"86","author":"HS Hreggvidsdottir","year":"2009","unstructured":"Hreggvidsdottir, H. S. et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 86, 655\u2013662 (2009).","journal-title":"J Leukoc Biol"},{"key":"BFsrep21890_CR24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-immunol-030409-101323","volume":"29","author":"U Andersson","year":"2011","unstructured":"Andersson, U. & Tracey, K. J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29, 139\u2013162 (2011).","journal-title":"Annu Rev Immunol"},{"key":"BFsrep21890_CR25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.mcn.2010.06.005","volume":"45","author":"V Meneghini","year":"2010","unstructured":"Meneghini, V., Francese, M. T., Carraro, L. & Grilli, M. A novel role for the Receptor for Advanced Glycation End-products in neural progenitor cells derived from adult SubVentricular Zone. Mol Cell Neurosci 45, 139\u2013150 (2010).","journal-title":"Mol Cell Neurosci"},{"key":"BFsrep21890_CR26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ncpendmet0786","volume":"4","author":"SF Yan","year":"2008","unstructured":"Yan, S. F., Ramasamy, R. & Schmidt, A. M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4, 285\u2013293 (2008).","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"BFsrep21890_CR27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/1352458507088105","volume":"14","author":"Z Sternberg","year":"2008","unstructured":"Sternberg, Z. et al. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler 14, 759\u2013763 (2008).","journal-title":"Mult Scler"},{"key":"BFsrep21890_CR28","doi-asserted-by":"crossref","first-page":"R817","DOI":"10.1186\/ar1749","volume":"7","author":"R Pullerits","year":"2005","unstructured":"Pullerits, R., Bokarewa, M., Dahlberg, L. & Tarkowski, A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 7, R817\u2013824 (2005).","journal-title":"Arthritis Res Ther"},{"key":"BFsrep21890_CR29","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/01.ATV.0000160342.20342.00","volume":"25","author":"C Falcone","year":"2005","unstructured":"Falcone, C. et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25, 1032\u20131037 (2005).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFsrep21890_CR30","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1096\/fj.04-1899com","volume":"18","author":"LL Rong","year":"2004","unstructured":"Rong, L. L. et al. Antagonism of RAGE suppresses peripheral nerve regeneration. FASEB J 18, 1812\u20131817 (2004).","journal-title":"FASEB J"},{"key":"BFsrep21890_CR31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nm831","volume":"9","author":"SS Yan","year":"2003","unstructured":"Yan, S. S. et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 9, 287\u2013293 (2003).","journal-title":"Nat Med"},{"key":"BFsrep21890_CR32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/2012","volume":"4","author":"L Park","year":"1998","unstructured":"Park, L. et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4, 1025\u20131031 (1998).","journal-title":"Nat Med"},{"key":"BFsrep21890_CR33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0022-510X(91)90313-V","volume":"104","author":"M Weller","year":"1991","unstructured":"Weller, M. et al. Comparative analysis of cytokine patterns in immunological, infectious and oncological neurological disorders. J Neurol Sci 104, 215\u2013221 (1991).","journal-title":"J Neurol Sci"},{"key":"BFsrep21890_CR34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1034\/j.1600-0404.2003.00179.x","volume":"109","author":"VV Radhakrishnan","year":"2004","unstructured":"Radhakrishnan, V. V., Sumi, M. G., Reuben, S., Mathai, A. & Nair, M. D. Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome. Acta Neurol Scand 109, 71\u201374 (2004).","journal-title":"Acta Neurol Scand"},{"key":"BFsrep21890_CR35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1085-9489.2005.10309.x","volume":"10","author":"M Kurz","year":"2005","unstructured":"Kurz, M., Pischel, H., Hartung, H. P. & Kieseier, B. C. Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system. J Peripher Nerv Syst 10, 311\u2013318, (2005).","journal-title":"J Peripher Nerv Syst"},{"key":"BFsrep21890_CR36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2006.11.027","volume":"183","author":"JM Taylor","year":"2007","unstructured":"Taylor, J. M. & Pollard, J. D. Soluble TNFR1 inhibits the development of experimental autoimmune neuritis by modulating blood-nerve-barrier permeability and inflammation. J Neuroimmunol 183, 118\u2013124 (2007).","journal-title":"J Neuroimmunol"},{"key":"BFsrep21890_CR37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.autrev.2011.05.012","volume":"11","author":"C Kamm","year":"2012","unstructured":"Kamm, C. & Zettl, U. K. Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev 11, 196\u2013202 (2012).","journal-title":"Autoimmun Rev"},{"key":"BFsrep21890_CR38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cca.2009.04.022","volume":"405","author":"HL Chiang","year":"2009","unstructured":"Chiang, H. L. et al. Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barre syndrome and other neurological disorders. Clin Chim Acta 405, 143\u2013147 (2009).","journal-title":"Clin Chim Acta"},{"key":"BFsrep21890_CR39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/ATVBAHA.112.300523","volume":"33","author":"SC Tang","year":"2013","unstructured":"Tang, S. C. et al. Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler Thromb Vasc Biol 33, 585\u2013594, ATVBAHA.112.300523 (2013).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFsrep21890_CR40","doi-asserted-by":"crossref","unstructured":"Lee, E. J. et al. Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation. FASEB J (2015).","DOI":"10.1096\/fj.15-272302"},{"key":"BFsrep21890_CR41","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2174\/092986706777585013","volume":"13","author":"D Geroldi","year":"2006","unstructured":"Geroldi D, Falcone C & Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 13(17), 1971\u20131978 (2006).","journal-title":"Curr Med Chem"},{"key":"BFsrep21890_CR42","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.192.4.565","volume":"192","author":"U Andersson","year":"2000","unstructured":"Andersson, U. et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192, 565\u2013570 (2000).","journal-title":"J Exp Med"},{"key":"BFsrep21890_CR43","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury, A. K. & Cornblath, D. R. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 27 Suppl, S21\u201324 (1990).","journal-title":"Ann Neurol"},{"key":"BFsrep21890_CR44","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","volume":"2","author":"RA Hughes","year":"1978","unstructured":"Hughes, R. A., Newsom-Davis, J. M., Perkin, G. D. & Pierce, J. M. Controlled trial prednisolone in acute polyneuropathy. Lancet 2, 750\u201353 (1978).","journal-title":"Lancet"},{"key":"BFsrep21890_CR45","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","volume":"6","author":"R van Koningsveld","year":"2007","unstructured":"van Koningsveld, R. et al. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 6, 589\u2013594 (2007).","journal-title":"Lancet Neurol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep21890","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep21890.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep21890.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:11:47Z","timestamp":1672841507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep21890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,4,20]]}},"alternative-id":["BFsrep21890"],"URL":"https:\/\/doi.org\/10.1038\/srep21890","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,23]]},"assertion":[{"value":"6 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21890"}}